| ||||||||||||||
|
|
|||||||||||||
From the Texas Anodyne Research Institute and Sherman Pain Care, Texas.
Address correspondence and reprint requests to Noor M. Gajraj, MD, FRCA, DABPM, 1111 Gallagher Dr., Sherman, TX 75090. Address e-mail to noorgajraj{at}aol.com.
Abstract
Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory neurotransmitter
-aminobutyric acid. It is an
2-
(
2-
) ligand that has analgesic, anticonvulsant, anxiolytic, and sleep-modulating activities. Pregabalin binds potently to the
2-
subunit of calcium channels, resulting in a reduction in the release of several neurotransmitters, including glutamate, noradrenaline, serotonin, dopamine, and substance P. In this review, I will discuss the pharmacology of pregabalin and available efficacy studies in pain management. This review will focus on the advances in pregabalin pharmacology since my previous review in 2005.
|